Characteristics | Number | Mean±SD | Range |
---|---|---|---|
Patients (eyes) | 50 (91) | ||
Gender (male/female) | 33/17 | ||
Complete type/incomplete type | 24/26 | ||
Bilateral/unilateral | 49/1 | ||
Age at the initial visit (years) | 37.4±10.6 | 14–60 | |
Onset age of ocular symptoms (years) | 33.0±10.6 | 13–59 | |
Duration between onset and initial visit (months) | 45.7±64.4 | 0–273 | |
Patients treated with/without colchicines | 39/11 | ||
Patients treated with/without ciclosporin | 22/28 | ||
Patients treated with/without prednisolone | 25/25 | ||
Patients treated with/without infliximab | 6/44 | ||
Patients treated with/without cyclophosphamide | 3/47 | ||
Patients treated with/without tacrolimus | 2/48 | ||
Patients treated with/without azathioprine | 2/48 | ||
Patients treated with/without methotrexate | 1/49 | ||
Total number of immunosuppressive medications used during the period | 2.0±1.1 | 0–4 | |
Cataract surgery during the period (eyes) | 22 | ||
Glaucoma surgery during the period (eyes) | 9 | ||
BCVA (logMAR) at the first remission | 0.16±0.30 | ||
BCVA (logMAR) at the last remission (after 5 years) | 0.21±0.37 | ||
Total number of ocular attacks (5 years) | 10.0±7.9 | 0–32 | |
BOS24-5Y | 36.8±40.8 | 0–296 | |
Anterior chamber cells-5Y | 11.9±12.4 | 0–78 | |
Vitreous opacity-5Y | 6.7±9.6 | 0–67 | |
Peripheral fundus lesions-5Y | 11.3±14.7 | 0–102 | |
Posterior pole lesions-5Y | 4.5±6.6 | 0–31 | |
Subfoveal lesions-5Y | 1.5±2.7 | 0–14 | |
Optic disc lesions-5Y | 0.8±1.7 | 0–8 |
BCVA, best-corrected visual acuity; BOS24-5Y, summation of BOS24 scores over a 5-year period; logMAR, logarithm of the minimum angle of resolution.